197 related articles for article (PubMed ID: 26634371)
1. Structural studies of UBXN2A and mortalin interaction and the putative role of silenced UBXN2A in preventing response to chemotherapy.
Sane S; Abdullah A; Nelson ME; Wang H; Chauhan SC; Newton SS; Rezvani K
Cell Stress Chaperones; 2016 Mar; 21(2):313-26. PubMed ID: 26634371
[TBL] [Abstract][Full Text] [Related]
2. Ubiquitin-like (UBX)-domain-containing protein, UBXN2A, promotes cell death by interfering with the p53-Mortalin interactions in colon cancer cells.
Sane S; Abdullah A; Boudreau DA; Autenried RK; Gupta BK; Wang X; Wang H; Schlenker EH; Zhang D; Telleria C; Huang L; Chauhan SC; Rezvani K
Cell Death Dis; 2014 Mar; 5(3):e1118. PubMed ID: 24625977
[TBL] [Abstract][Full Text] [Related]
3. UBXN2A enhances CHIP-mediated proteasomal degradation of oncoprotein mortalin-2 in cancer cells.
Sane S; Hafner A; Srinivasan R; Masood D; Slunecka JL; Noldner CJ; Hanson AD; Kruisselbrink T; Wang X; Wang Y; Yin J; Rezvani K
Mol Oncol; 2018 Oct; 12(10):1753-1777. PubMed ID: 30107089
[TBL] [Abstract][Full Text] [Related]
4. A plant alkaloid, veratridine, potentiates cancer chemosensitivity by UBXN2A-dependent inhibition of an oncoprotein, mortalin-2.
Abdullah A; Sane S; Branick KA; Freeling JL; Wang H; Zhang D; Rezvani K
Oncotarget; 2015 Sep; 6(27):23561-81. PubMed ID: 26188124
[TBL] [Abstract][Full Text] [Related]
5. Nucleocytoplasmic Translocation of UBXN2A Is Required for Apoptosis during DNA Damage Stresses in Colon Cancer Cells.
Abdullah A; Sane S; Freeling JL; Wang H; Zhang D; Rezvani K
J Cancer; 2015; 6(11):1066-78. PubMed ID: 26516353
[TBL] [Abstract][Full Text] [Related]
6. MEK5/ERK5 signaling inhibition increases colon cancer cell sensitivity to 5-fluorouracil through a p53-dependent mechanism.
Pereira DM; Simões AE; Gomes SE; Castro RE; Carvalho T; Rodrigues CM; Borralho PM
Oncotarget; 2016 Jun; 7(23):34322-40. PubMed ID: 27144434
[TBL] [Abstract][Full Text] [Related]
7. Mortaparib, a novel dual inhibitor of mortalin and PARP1, is a potential drug candidate for ovarian and cervical cancers.
Putri JF; Bhargava P; Dhanjal JK; Yaguchi T; Sundar D; Kaul SC; Wadhwa R
J Exp Clin Cancer Res; 2019 Dec; 38(1):499. PubMed ID: 31856867
[TBL] [Abstract][Full Text] [Related]
8. UBXN2A, a Ubiquitin-Like Protein, Alters Proteins in mTORC2 Pathway.
Reihe C
S D Med; 2022 Oct; 75(10):456-458. PubMed ID: 36889268
[TBL] [Abstract][Full Text] [Related]
9. In silico analysis of the binding properties of solasonine to mortalin and p53, and in vitro pharmacological studies of its apoptotic and cytotoxic effects on human HepG2 and Hep3b hepatocellular carcinoma cells.
Pham MQ; Tran THV; Pham QL; Gairin JE
Fundam Clin Pharmacol; 2019 Aug; 33(4):385-396. PubMed ID: 30628118
[TBL] [Abstract][Full Text] [Related]
10. Reconstitution of the mitochondrial Hsp70 (mortalin)-p53 interaction using purified proteins--identification of additional interacting regions.
Iosefson O; Azem A
FEBS Lett; 2010 Mar; 584(6):1080-4. PubMed ID: 20153329
[TBL] [Abstract][Full Text] [Related]
11. Withanone binds to mortalin and abrogates mortalin-p53 complex: computational and experimental evidence.
Grover A; Priyandoko D; Gao R; Shandilya A; Widodo N; Bisaria VS; Kaul SC; Wadhwa R; Sundar D
Int J Biochem Cell Biol; 2012 Mar; 44(3):496-504. PubMed ID: 22155302
[TBL] [Abstract][Full Text] [Related]
12. UBXN2A suppresses the Rictor-mTORC2 signaling pathway, an established tumorigenic pathway in human colorectal cancer.
Sane S; Srinivasan R; Potts RA; Eikanger M; Zagirova D; Freeling J; Reihe CA; Antony RM; Gupta BK; Lynch D; Bleeker J; Turaihi H; Pillatzki A; Zhou W; Luo X; Linnebacher M; Agany D; Zohim EG; Humphrey LE; Black AR; Rezvani K
Oncogene; 2023 May; 42(21):1763-1776. PubMed ID: 37037900
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Fas expression by RNAi modulates 5-fluorouracil-induced apoptosis in HCT116 cells expressing wild-type p53.
Borralho PM; Moreira da Silva IB; Aranha MM; Albuquerque C; Nobre Leitão C; Steer CJ; Rodrigues CM
Biochim Biophys Acta; 2007 Jan; 1772(1):40-7. PubMed ID: 17056233
[TBL] [Abstract][Full Text] [Related]
14. Activation of wild type p53 function by its mortalin-binding, cytoplasmically localizing carboxyl terminus peptides.
Kaul SC; Aida S; Yaguchi T; Kaur K; Wadhwa R
J Biol Chem; 2005 Nov; 280(47):39373-9. PubMed ID: 16176931
[TBL] [Abstract][Full Text] [Related]
15. Identification and characterization of molecular interactions between mortalin/mtHsp70 and HSP60.
Wadhwa R; Takano S; Kaur K; Aida S; Yaguchi T; Kaul Z; Hirano T; Taira K; Kaul SC
Biochem J; 2005 Oct; 391(Pt 2):185-90. PubMed ID: 15957980
[TBL] [Abstract][Full Text] [Related]
16. Tumor suppression by apoptotic and anti-angiogenic effects of mortalin-targeting adeno-oncolytic virus.
Yoo JY; Ryu J; Gao R; Yaguchi T; Kaul SC; Wadhwa R; Yun CO
J Gene Med; 2010 Jul; 12(7):586-95. PubMed ID: 20603860
[TBL] [Abstract][Full Text] [Related]
17. Chloroquine enhances the chemotherapeutic activity of 5-fluorouracil in a colon cancer cell line via cell cycle alteration.
Choi JH; Yoon JS; Won YW; Park BB; Lee YY
APMIS; 2012 Jul; 120(7):597-604. PubMed ID: 22716215
[TBL] [Abstract][Full Text] [Related]
18. 5-FU targets rpL3 to induce mitochondrial apoptosis via cystathionine-β-synthase in colon cancer cells lacking p53.
Pagliara V; Saide A; Mitidieri E; d'Emmanuele di Villa Bianca R; Sorrentino R; Russo G; Russo A
Oncotarget; 2016 Aug; 7(31):50333-50348. PubMed ID: 27385096
[TBL] [Abstract][Full Text] [Related]
19. Crystal structure of the nucleotide-binding domain of mortalin, the mitochondrial Hsp70 chaperone.
Amick J; Schlanger SE; Wachnowsky C; Moseng MA; Emerson CC; Dare M; Luo WI; Ithychanda SS; Nix JC; Cowan JA; Page RC; Misra S
Protein Sci; 2014 Jun; 23(6):833-42. PubMed ID: 24687350
[TBL] [Abstract][Full Text] [Related]
20. Identifications small molecules inhibitor of p53-mortalin complex for cancer drug using virtual screening.
Utomo DH; Widodo N; Rifa'i M
Bioinformation; 2012; 8(9):426-9. PubMed ID: 22715313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
